Melanoma is the third most common systemic cancer that leads to brain metastases. The annual incidence of melanoma has increased over time, with brain metastases developing in 40% to 50% of patients with advanced melanoma. Traditional management of melanoma-related brain metastases has focused on symptom control as a result of the significant neurologic morbidity associated with the disease. Median overall survival for these patients, if untreated, is approximately 3 months. As with other brain metastases, a multidisciplinary treatment approach that includes surgery and radiation therapy is typically used, with historically little role for systemic, cytotoxic therapy. During the past decade, advancement within the field of genomics has led to the identification of melanoma-specific mutations, namely, v-Raf murine sarcoma viral oncogene homolog B and neuroblastoma RAS viral oncogene homolog, as well as to the development of agents that target these driver mutations. In addition, the advent of immunotherapies, specifically, agents that target cytotoxic T-lymphocyte antigen-4, anti-programmed death-1, and programmed death ligand-1, has increased the potential therapeutic options available to patients with both systemic and brain disease. With these advances, early trials have demonstrated improved overall survival in patients with brain metastases who receive these therapies either as single agents or as part of multimodality treatment regimens.
INTRODUCTION
Brain metastases, as in other systemic cancers, such as lung or breast, remain a significant complication of melanoma. Recent data have shown an incidence of brain metastases in # 50% of patients with metastatic melanoma. 1 Because this is typically a late complication of systemic disease, melanomarelated brain metastases have been associated with significant neurologic morbidity and a poor median overall survival, with treatment, of approximately 9 months. 2 Factors that predict survival include age, performance status, and the number of brain metastases, which are summarized as the melanoma-specific graded prognostic assessment. 3 Until recently, management of brain metastases has primarily focused on local, intracranial control of disease. In cases of single metastatic lesions or large, symptomatic lesions in oligometastatic disease, resection is typically advised. For patients with more than a single brain metastasis, radiation therapy, including stereotactic radiosurgery and whole-brain radiation therapy, has been the mainstay of treatment. 4 As long-term data from postwhole-brain radiation therapy outcomes have emerged, the modality is used less frequently because of the risk of neurocognitive decline. Historically, systemic or cytotoxic therapies have not played a prominent role mainly because of the challenges of penetrating the blood-brain barrier and of achieving activity within the CNS. Recently, emergence of novel genomic techniques-whole-exome and next-generation sequencing-has enabled the identification of driver mutations in melanoma. Such specific targets as the neuroblastoma RAS viral oncogene homolog (NRAS) and v-Raf murine sarcoma viral oncogene homolog B (BRAF) have been exploited for therapeutic use. Furthermore, immunotherapy has revolutionized the management of melanoma, specifically, with inhibition of cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed death-1 (PD-1), which is expressed on lymphocytes, and programmed death ligand-1, which is expressed on tumor cells. 5 In this review, we discuss advances in the management approach to brain metastases in patients with melanoma and we highlight the current and potential therapeutic options for the management of this devastating disease.
ASSESSING OUTCOMES IN METASTATIC MELANOMA
To predict patient outcomes, both before and after treatment, scales have been developed to identify patients who are most likely to benefit from therapy. The earliest of the scoring algorithms, the Radiation Therapy Oncology Group recursive partitioning analysis, summarizes the risk factors most likely to impact survival, as generated from prior investigations of patients with brain metastases from multiple types of malignancies. 6 From this paradigm, factors that have been associated with favorable prognosis included age , 65 years, Karnofsky performance score (KPS) $ 70, and the brain as the only site of metastasis, all of which correlate with a median overall survival of 7.1 months. In contrast, patients with KPS , 70 had a median survival of 2.3 months. 6 On the basis of this analysis, three prognostic classes were identified, correlating with clinical outcomes (Table 1) . A limitation of the recursive partitioning analysis is that the inherent heterogeneity of brain metastases and the site of origin are not integrated into outcomes. More recently, the disease-specific graded prognostic assessment, which also incorporates the primary cancer, was developed. 7 In a melanomaspecific brain metastasis graded prognostic assessment, KPS and the number of brain metastases were statistically significant factors. The scale uses scores that range from 0 to 4, correlating with median survival in months ( Table 2) . As we enter an era of precision medicine, other limitations to the traditionally used scoring systems have been identified, including reliance on clinical data without consideration of the extent of disease (extracranial metastatic burden, leptomeningeal dissemination), size of the lesion, tumor genetics at the time of diagnosis, or use of novel, targeted drugs as part of a treatment regimen. 8, 9 With the increased use of genomics to achieve an integrated diagnosis (histology and somatic mutation), unique molecular drivers that are specific to melanoma brain metastases have been identified. 10 Previous data have not been conclusive in determining whether these mutations-BRAF and NRAS-are risk factors for the development of brain metastases. 11 In the future, we expect that these will be included when deriving prognostic information for patients.
GENERAL PRINCIPLES OF MANAGEMENT OF BRAIN METASTASES FROM MELANOMA Surgery
Resection is mainly limited to patients with a solitary or single brain metastasis and is often performed for symptomatic relief. Compared with radiation therapy alone, an overall survival benefit in all patients with single brain metastases who undergo resection has been demonstrated. 12 There may also be a role for resection in oligometastatic disease of dominant, symptomatic lesions. As the field comes closer to achieving integrated histologic and genetic diagnoses for these patients, a secondary benefit of debulking is the procurement of adequate tumor tissue for molecular characterization. Investigators in one study compared the genomics of matched brain metastases and primary tumors across multiple histologies and demonstrated that . 50% of brain metastases harbored genetic alterations that were not detected in the clinically sampled primary tumor.
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Radiation Therapy Whole-brain radiation therapy Use of whole-brain radiation therapy in the treatment of oligometastatic disease in patients with melanoma has been challenged by a number of factors, including inherent radioresistance of melanoma, recent improvement of CNSdirected cytotoxic therapies, and concern for neurocognitive sequelae after treatment. Whole-brain radiation therapy has been shown to confer a survival benefit in patients with a favorable prognostic profile on the basis of on KPS, age, and number of extracranial metastases (graded prognostic assessment, class I). 7 In randomized studies, whole-brain radiation therapy after resection or radiosurgery did not confer an overall survival benefit; however, this therapy did improve intracranial disease control and lessened the risk of death secondary to neurologic causes. 13 Standard whole-brain radiation therapy treatment regimens have established a total dose of 30 Gy fractionated over 2 to 3 weeks. To mitigate the risk of neurocognitive adverse effects, delivery of whole-brain radiation therapy has been modified. Neurocognitive battery tests postradiation have shown that the greatest deficits are in memory and learning.
14 Neural injury and subsequent decline has been determined to be the result of damage to radiosensitive neural progenitor cells within the subgranular zone of the hippocampus. 15 Conformal avoidance of the hippocampus during whole-brain radiation therapy as a technique to preserve memory and learning is being investigated, with results suggestive of a trend toward improved quality of life. 16 The percentage of patients with disease within or surrounding the hippocampus-within a 5-mm margin-is low 14 ; therefore, overall treatment efficacy may not be compromised.
Other measures for the preservation of neurocognitive function with whole-brain radiation therapy include the prophylactic use of memantine, an oral N-methyl D-aspartate receptor antagonist. In patients who were administered memantine concurrently with whole-brain radiation therapy, there was no significant difference in memory decline compared with patients who did not receive memantine; however, there was a delay in the onset of cognitive decline and an improvement in other aspects of the neurocognitive battery that favored the memantine group. For these reasons, some authorities advocate the use of memantine concurrent with and for 6 months after whole-brain radiation therapy. 17 
Stereotactic radiosurgery
Unlike with whole-brain radiation therapy, efficacy of stereotactic radiosurgery is not influenced by the primary tumor of origin. As with surgical resection, stereotactic radiosurgery has been most beneficial in achieving local control of small (, 3 cm) lesions in patients with fewer than three total lesions. 12 Other factors that impact the decision to pursue surgery versus stereotactic radiosurgery include lesion location-if surgically inaccessible or eloquent cortex-and the surgical candidacy of the patient. To date, there have been no randomized trials that have evaluated the efficacy of local control with stereotactic radiosurgery versus surgery. A phase III trial demonstrated that in patients with one to three brain metastases, addition of whole-brain radiation therapy to stereotactic radiosurgery resulted in improved local control; however, overall survival did not improve, and results also showed decline in cognitive function compared with stereotactic radiosurgery alone.
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Targeted Therapies BRAF mutations are present in # 50% of patients with advanced melanoma and should be investigated if a patient presents at this stage. Approximately 90% of the BRAF mutations in cutaneous melanoma are valine to glutamic acid substitution (Val600Glu, V600E); there are other known activating mutations, including valine to lysine (Val600Lys, V600K), which constitute a smaller percentage. 19 Introduction of BRAF-targeted agents in patients who harbor these mutations has led to rapid systemic disease responses within weeks of initiation of therapy, which has prompted the same investigations in the management of intracranial disease. Currently, there are two US Food and Drug Administration-approved BRAF inhibitors available for clinical use: vemurafenib, the first agent licensed for treatment of BRAF-mutant metastatic melanoma, and dabrafenib. It is not yet clear whether these agents have a differential effect on disease according to the specific mutation type (V600E v V600K). 14 
Vemurafenib
Vemurafenib was first identified and demonstrated a survival benefit compared with prior cytotoxic therapy (dacarbazine) in patients with metastatic melanoma. 19 In a phase III trial, BRAF-mutant patients with metastatic or unresectable stage IIIc disease were randomly assigned to receive either vemurafenib or dacarbazine, with primary end points of overall survival and progression-free survival. Patients with brain metastases that had progressed or had been treated within the previous 3 months were excluded. In patients treated with vemurafenib, there was both increased overall survival at 6 months (84% v 64%, respectively) and increased progression-free survival (5.3 months v 1.6 months, respectively) compared with dacarbazine. Prolongation of overall survival was observed in patients with BRAF V600E mutations. 19 Investigation of vemurafenib in intracranial disease has produced similar improvements in overall and progression-free survival. A retrospective review from a single institution of 24 patients with brain metastases who were treated with vemurafenib showed response rates of 71% and 50% in intra-and extracranial disease, respectively, which are much higher than historical controls. 20 In patients from this study who experienced a poor response to vemurafenib and earlier disease progression, activation mutations in PIK3CA or inactivation of PTEN were present, which contributed to the poor sensitivity of the tumor to vemurafenib.
Dabrafenib
Early-phase studies of dabrafenib, an inhibitor of BRAF kinase, demonstrated activity in patients with BRAF V600E-mutant melanoma with asymptomatic brain metastases. 21 The BREAK-MB (BRAF-mutant melanoma metastatic to the brain) study was a phase II trial that investigated response rates of dabrafenib in patients with untreated or recurrent disease. Patients with V600E mutations had response rates of 39% in the treatment-naïve group and 31% in the recurrent group compared with 6.7% in the treatment-naïve group and 22.2% in the recurrent group of patients with V600K mutation. 22 In addition, improvements in overall and progression-free survival were demonstrated.
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Mitogen-activated protein kinase kinase inhibitors Selective mitogen-activated protein kinase kinase (MEK) inhibition has also been explored as a potential therapeutic target in melanoma and has been combined with BRAF inhibitors.
Results suggest an additional survival benefit compared with BRAF inhibitor therapy alone. MEK exists downstream of BRAF in the mitogen-activated protein kinase signaling pathway, which makes the combination of inhibitors an attractive therapeutic option because resistance to BRAF inhibitor monotherapy may be reduced with the addition of MEK inhibition. In phase I and II trials in BRAF V600-mutant metastatic melanoma, combination of dabrafenib and trametinib, an MEK inhibitor, resulted in a median overall survival of 2 years and a progression-free survival of 3 years compared with vemurafenib monotherapy. As expected, patients with a favorable prognostic profile experienced a more durable response. 23 In addition, there were similarities in the incidences of grade 3 or 4 toxic effects and adverse effects, which led to dose reduction. Skin-related adverse effects were less frequent in the dabrafenib and trametinib arm. 23 Thus far, no data exist for use of MEK inhibitor monotherapy in patients with melanoma-related brain metastases.
Immunotherapies
As it has in other solid tumors, the role of immunotherapies has increased in the management of metastatic melanoma. Interleukin-2 was the earliest immunotherapy agent to be used in melanoma. Unfortunately, whereas it demonstrated some efficacy, it was associated with severe toxicity, notably, fluid retention and capillary leak syndrome, which led to increased peritumoral edema. 24 Subsequently, high-dose interleukin-2 (HDIL-2) treatment was studied; however, there are little data to report on the outcome of patients with brain metastases who received HDIL-2.
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The next generation of immunotherapy agents have focused on immune checkpoint inhibitors, such as CTLA-4, PD-1, and programmed death ligand-1 antibodies. Ipilimumab, a CTLA-4 monoclonal antibody, has demonstrated improved survival in metastatic melanoma and in patients with melanoma brain metastases. A phase II trial of ipilimumab in patients with small and asymptomatic brain metastases-that did not require corticosteroids-demonstrated that 24% of patients achieved a partial response or stable disease. 25 In the NIBIT-M1 study, there was demonstrated clinical activity in patients with advanced melanoma who were treated with ipilimumab and fotemustine, including in patients with brain metastases. 26 A subsequent 3-year analysis demonstrated the efficacy of this combination without impairment of the immunologic activity of ipilimumab.
5
The NIBIT-M2 study, a randomized, phase III trial, will compare overall survival in treatment with fotemustine alone versus ipilimumab plus fotemustine versus ipilimumab plus nivolumab (a PD-1 inhibitor) as first-line therapy in patients with symptomatic brain metastases. In addition, the role of pembrolizumab, a PD-1 blocking antibody, is being investigated in patients with melanoma and brain metastases. 20 Although rare, there have been reports of neurologic toxicities associated with immune checkpoint blockade. Among those reported as immune-related adverse events are transient peripheral neuropathies, which have been reported in , 1% of patients who received ipilimumab. 27 Recommended management in the event of grade 2 neuropathy-no interference in daily activities-is an oral steroid taper and to continue at the same dose of ipilimumab. 28 For more severe grade 3 or 4 neuropathy, systemic corticosteroids and discontinuation of ipilimumab are recommended. 28 Other case reports of neurologic disease have described optic neuritis, aseptic meningitis, myasthenia gravis, and Guillain-Barre syndrome.
29

Symptom Management
The principles of management of neurologic symptoms secondary to brain metastases from melanoma do not differ significantly from the management of primary brain tumors. Treatment is focused around control of vasogenic brain edema as a result of tumor-or disease-directed therapies and the symptoms that can develop. Corticosteroids are a mainstay of this management regimen and may be used in the control of headaches, weakness, or other focal neurologic symptoms that are attributable to cerebral edema. Dexamethasone is the preferred corticosteroid, and the goal of practitioners should be its use at the lowest effective dose for the patient, given the adverse effects associated with long-term use of high-dose corticosteroids, including myopathy, opportunistic infections, hyperglycemia, and mood instability. To date, there are no consensus guidelines regarding dosing, timing, or duration of treatment. 30 Use of corticosteroids has become more complex in the era of immunotherapies. In this context, the effect of immunotherapy may be abrogated by concurrent use of corticosteroids; therefore, use is avoided if clinically appropriate. 31 Because seizures may result from increased edema or tumor growth, antiseizure medications are used for management in patients with a known history of seizure. To date, there has not been a demonstrated benefit in the prevention of seizure with prophylaxis.
32, 33 In patients with an established history of seizures, the newer, nonenzyme-inducing agents, such as levetiracetam and lacosamide, are favored because of their improved tolerance, convenient dosing, and equivalent efficacy as well as reduced impact on disease-directed therapies compared with older generations of enzyme-inducing agents.
In conclusion, brain metastases in patients with advanced and metastatic melanoma are a frequent complication and a significant cause of morbidity and mortality in this patient population. As the incidence of brain metastases continues to increase in patients with metastatic melanoma, it is urgent that we identify effective therapies. During the past decade, management of melanoma has continued to evolve. In the era of whole-exome and next-generation sequencing, there is a requisite role for identification of driver mutations, specifically, BRAF, given the possibility for targeted therapies and the opportunity for improved survival. Moving forward, trials that investigate multimodal treatment regimens-combinations of targeted or immunotherapies with surgery or radiation-will answer additional questions regarding the optimization of management in this growing patient population (Table 3) .
